Ionis Pharmaceuticals (NASDAQ: IONS) reported Q2 EPS of ($0.74), $0.13 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $134 million versus the consensus estimate of $140.73 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.